Insulin and Cardiovascular Disease: Pressure on the Pipes

Insulin resistance does not stay confined to fat cells.

Once insulin signaling is impaired, its effects spread across vascular, lipid, and inflammatory systems.

In blood vessels, insulin normally stimulates nitric oxide production, allowing arteries to relax and maintain healthy flow. With insulin resistance, that signal weakens—vessels become stiffer, endothelial function declines, and blood pressure regulation deteriorates.

In the liver, elevated insulin shifts lipid handling. Instead of exporting fat efficiently, the liver packages more triglycerides into circulation while suppressing fat oxidation. Triglycerides rise, HDL often falls, and lipid particles become more atherogenic.

In fat tissue, insulin’s strongest action is not fat creation, it’s fat retention. By suppressing hormone-sensitive lipase, insulin prevents stored fat from being released, even when energy demand is present. Fat becomes trapped, particularly in visceral depots that actively signal inflammation.

At the same time, chronically elevated insulin promotes low-grade inflammatory signaling and oxidative stress, further damaging vascular tissue and worsening insulin sensitivity, a self-reinforcing loop.

This is why cardiovascular disease clusters so tightly with diabetes, abdominal obesity, and metabolic syndrome.

Different pipes.
Same pressure source.